Are you a financial expert?Login
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup

AARTIDRUGS

2,345
+126.25 (5.69%)
Updated 03:29 07/08 IST

AARTIDRUGS Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for AARTIDRUGS
Disclaimer
0% Bullish
0% Bearish

AARTIDRUGS Buy or Sell - Brokerage Reports

No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
796
Consensus Potential
-178.74%
See AARTIDRUGS Share Price Targets >>

AARTIDRUGS Ratings

Long term AARTIDRUGS rating by FrontPage users
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
5/5 (1 Ratings)
Find answers to all your questions on live AARTIDRUGS message board: Is AARTIDRUGS buy or sell? Should I buy AARTIDRUGS shares? Why are AARTIDRUGS shares falling? Should I invest in AARTIDRUGS stock?

  1. Home
  2. AARTIDRUGS Forum

AARTIDRUGS Share Price Discussion

M
Mayur @mayurgoyal
Reputation: 86,074 • Yesterday 5:22 AM
Type
Sell
Instrument
AARTIDRUGS
Entry Price
₹2,375
Price@Trade
₹2,375
Target Price
₹2,270
Stop Price
₹2,410
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹237,500 approx for 100 Qty
Status
Active
#AARTIDRUGS
Like
Reply
M
Mayur @mayurgoyal
Reputation: 86,074 • Yesterday 5:06 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,275
Price@Trade
₹2,335.75
Target Price
₹2,662
Stop Price
₹2,200
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹227,500 approx for 100 Qty
Status
Waiting for entry
#AARTIDRUGS
Like
Reply
M
Mayur @mayurgoyal
Reputation: 86,074 • Yesterday 4:34 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,437
Price@Trade
₹2,437
Target Price
₹2,620
Stop Price
₹2,340
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹24,370 approx for 10 Qty
Status
Stoploss Hit
Exit Price
₹2,340
Net P&L
-₹970 (-3.98%)
#AARTIDRUGS
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
Yesterday 5:06 AM
Update
Stoploss Hit
Exit Price
₹2,340
M
Mayur @mayurgoyal
Reputation: 86,074 • Yesterday 3:42 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,555
Price@Trade
₹2,468.65
Target Price
₹2,660
Stop Price
₹2,510
Valid Till
Aug 7, 2020 3:20 AM
Margin
₹2,555 approx for 1 Qty
Status
Waiting for entry
#AARTIDRUGS
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Yesterday 2:03 AM
Trade Spotlight: Aarti Drugs, Caplin Point & Aurobindo Pharma hit 52-week high, what should investors do?
Experts are of the view that investors should trade with caution, and a more sustainable move can be seen only a close above 11225. Immediate support is placed at 11,100 levels.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Aug 6 8:56 AM
Share market update: BSE Smallcap index up; Astral Poly Tech zooms 14%
The S&P BSE SmallCap index was trading 0.99 per cent up at 13561.88.
The Economic Times
Like
Reply
M
Mayur @mayurgoyal
Reputation: 86,074 • Aug 6 3:34 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,035.9
Price@Trade
₹2,035.9
Target Price
₹2,100
Stop Price
₹2,020
Valid Till
Aug 6, 2020 3:20 AM
Margin
₹20,359 approx for 10 Qty
Status
Target Achieved
Exit Price
₹2,100
Net P&L
+₹641 (+3.15%)
#AARTIDRUGS
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
Aug 6 8:22 AM
Update
Target Achieved
Exit Price
₹2,100
M
Mayur @mayurgoyal
Reputation: 86,074 • Aug 6 3:33 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,110
Price@Trade
₹2,065
Target Price
₹2,240
Stop Price
₹2,047
Valid Till
Aug 6, 2020 3:20 AM
Margin
₹105,500 approx for 50 Qty
Status
Exited before entry
#AARTIDRUGS
Like
Reply (1)
Latest replies
Mayur @mayurgoyal
•
Aug 6 5:24 AM
Update
Exited before entry
Price @ Update
₹2,035.15
M
Mayur @mayurgoyal
Reputation: 86,074 • Aug 6 3:29 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,110
Price@Trade
₹2,068
Target Price
₹2,230
Stop Price
₹2,040
Valid Till
Aug 6, 2020 3:20 AM
Margin
₹2,110,000 approx for 1000 Qty
Status
Exited before entry
#AARTIDRUGS
Like
Reply (1)
Latest replies
Mayur @mayurgoyal
•
Aug 6 3:30 AM
Update
Exited before entry
Price @ Update
₹2,068.95
N
Nagu @nagu-H1jJ9i_eS
Reputation: 190 • Aug 6 3:25 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹2,074
Price@Trade
₹2,062
Target Price
₹2,200
Stop Price
₹2,000
Valid Till
Sep 4, 2020 3:20 AM
Margin
₹995,520 approx for 480 Qty
Status
Exited
Exit Price
₹2,069
Net P&L
-₹2,400 (-0.24%)
#AARTIDRUGS
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
•
Aug 6 3:28 AM
Update
Trade Entered
Entry Price
₹2,074
Nagu @nagu-H1jJ9i_eS
•
Aug 6 3:30 AM
Update
Exited
Exit Price
₹2,069
Net P&L
-₹2,400 (-0.24%)
N
NewsBot @newsbot
Reputation: 4,721 • Aug 5 10:43 AM
Being Atmanirbhar: India Inc takes baby steps to move away from Chinese dependence
The critical factor is this - can Indian companies and the government keep their foot on the pedal, even after the nationalism fervour subsides.
Moneycontrol
Like
Reply
M
Manish Bhardwaj @manish006bhardwaj
Reputation: -374 • Aug 5 8:49 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹1,882.9
Price@Trade
₹1,882.9
Target Price
₹1,950
Stop Price
₹1,830
Valid Till
Aug 12, 2020 3:20 AM
Margin
₹188,290 approx for 100 Qty
Status
Target Achieved
Exit Price
₹1,950
Net P&L
+₹6,710 (+3.56%)
#AARTIDRUGS
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
Aug 6 2:52 AM
Update
Target Achieved
Exit Price
₹1,950
N
NewsBot @newsbot
Reputation: 4,721 • Aug 5 4:03 AM
Over 70 stocks in BSE500 hit 52-week high in July; time to chase momentum?
Experts say going ahead auto, pharma and chemicals sector look attractive. Analysts name 20 stocks that have a potential to outperform in August. These include Wockhardt, PI Industries and Rallis India
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Aug 4 4:36 AM
13 Covid-negative businesses double profit in Q1, Street rewarding them
April-June quarter earnings show several businesses from across sectors such as FMCG, agriculture, pharmaceutical, IT and e-commerce remained unscathed by the business disruption.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Jul 30 1:28 AM
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China
Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Jul 30 12:23 PM
Buy Aarti Drugs; target of Rs 2090: Anand Rathi
Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 2090 in its research report dated July 28, 2020.
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Jul 28 3:28 AM
Aarti Drugs Standalone June 2020 Net Sales at Rs 475.55 crore, up 28.52% Y-o-Y
Moneycontrol
Like
Reply
N
NewsBot @newsbot
Reputation: 4,721 • Jul 28 3:18 AM
Aarti Drugs Consolidated June 2020 Net Sales at Rs 544.67 crore, up 34.34% Y-o-Y
Moneycontrol
Like
Reply
M
Manish rajdev @manishrajdev
Reputation: 484 • Jul 27 8:57 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹1,751
Price@Trade
₹1,755
Target Price
₹1,765
Stop Price
₹1,740
Valid Till
Jul 28, 2020 3:20 AM
Margin
₹175,100 approx for 100 Qty
Status
Target Achieved
Exit Price
₹1,765
Net P&L
+₹1,400 (+0.8%)
#AARTIDRUGS
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
•
Jul 27 8:58 AM
Update
Trade Entered
Entry Price
₹1,751
TrackerBot @trackerbot
•
Jul 27 8:59 AM
Update
Target Achieved
Exit Price
₹1,765
P
Profit Bull @profitbulltelegram
Reputation: 13,762 • Jul 1 4:21 AM
Type
Buy
Instrument
AARTIDRUGS
Entry Price
₹1,299.95
Price@Trade
₹1,299.95
Target Price
₹1,350
Stop Price
₹1,260
Valid Till
Jul 8, 2020 3:20 AM
Margin
₹259,990 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹1,260
Net P&L
-₹7,990 (-3.07%)
#AARTIDRUGS
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
•
Jul 2 3:43 AM
Update
Stoploss Hit
Exit Price
₹1,260
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
Join FrontPage

  • AARTIDRUGS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization1,510.18
    Enterprise Value1,947.33
    Price to Earnings16.37
    Price to Book Value2.91
    Return on Capital Employed0.15
    Return on Equity0.17
    Face Value10
    Dividend YieldNA

  • AARTIDRUGS - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    18-Jun-19AnandRathiBuy796
    4-Oct-18CentrumBuy910
    14-Jun-18AnandRathiBuy720
    15-Jan-18CentrumBuy940
    AARTIDRUGS Brokerage Price Target

  • AARTIDRUGS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Aug 7230025502281.252356.45
    Aug 619102257.9519002218.75
    Aug 51747.25190417401881.65
    Aug 417501751.517011732.75
    Aug 3177117941727.41747

  • AARTIDRUGS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,649.76
    30 Day Moving Average₹1,533.17
    50 Day Moving Average₹1,332.14
    100 Day Moving Average₹998.71
    200 Day Moving Average₹783.45

  • AARTIDRUGS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue1,1401,092.260.04
    Operating Profit185181.280.02
    Profit Before Tax112106.540.05
    Net Income7374.24-0.02

  • AARTIDRUGS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds5194320.2
    Total Liabilities862881-0.02
    Total Assets1,3801,3140.05

  • AARTIDRUGS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity61174.21-0.65
    Cash from Investing Activity-71-96.29-0.26
    Cash from Financing Activity9-78.42-1.11
    Net Cash FlowNA-0.5-1

  • AARTIDRUGS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.07
    Return on Equity0.170.19
    Return on Capital Employed0.150.17

  • AARTIDRUGS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.05
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.06
    3 Year CAGR Growth in Net Income-0.06
    3 Yr CAGR Growth - Diluted EPS-0.03

  • AARTIDRUGS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.38
    5 Year CAGR Growth in Operating Profit0.5
    5 Year CAGR Growth in EBIDTA0.5
    5 Year CAGR Growth in Net Income0.61
    3 Yr CAGR Growth - Diluted EPS-0.17

  • AARTIDRUGS - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 2:03 AM
    Trade Spotlight: Aarti Drugs, Caplin Point & Aurobindo Pharma hit 52-week high, what should investors do?
    Moneycontrol
    NewsBot
    Aug 6 8:56 AM
    Share market update: BSE Smallcap index up; Astral Poly Tech zooms 14%
    The Economic Times
    NewsBot
    Aug 5 10:43 AM
    Being Atmanirbhar: India Inc takes baby steps to move away from Chinese dependence
    Moneycontrol
    NewsBot
    Aug 5 4:03 AM
    Over 70 stocks in BSE500 hit 52-week high in July; time to chase momentum?
    Moneycontrol
    NewsBot
    Aug 4 4:36 AM
    13 Covid-negative businesses double profit in Q1, Street rewarding them
    The Economic Times
    NewsBot
    Jul 30 1:28 AM
    Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China
    Moneycontrol
    NewsBot
    Jul 30 12:23 PM
    Buy Aarti Drugs; target of Rs 2090: Anand Rathi
    Moneycontrol
    NewsBot
    Jul 28 3:28 AM
    Aarti Drugs Standalone June 2020 Net Sales at Rs 475.55 crore, up 28.52% Y-o-Y
    Moneycontrol
    NewsBot
    Jul 28 3:18 AM
    Aarti Drugs Consolidated June 2020 Net Sales at Rs 544.67 crore, up 34.34% Y-o-Y
    Moneycontrol
    NewsBot
    Jun 4 4:41 AM
    Share market update: 20 stocks hit 52-week highs on NSE
    The Economic Times

  • AARTIDRUGS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
Privacy•Terms•••
FrontPage © 2020